The medical community that matter are those that are directly involved on a day to day basis in the treatment of men with ED.There have been a steady stream of them singing praises about Med3000
Your one quote from an obscure magazine was badly written by someone who failed to provide either his/her name or credentials.
I think I will stick to those in the business.
After all who would take advice on brain surgery from a librarian?
It is not a durex ring it is a topical treatment.
It will likely be labelled clinically proven.
It will sell like hot cakes.
"Assuming a smooth regulatory pathway, MED3000 would be the first clinically
proven ED product that is approved OTC in Europe and the US. Its rapid onset of
effect, undoubted safety, and ease of use suggest MED3000 would offer an
attractive, clearly differentiated (not ‘me too’), and competitive clinical profile
compared not only to the market leading class of PDE5 inhibitors, but other
classes of competing ED therapies. Management has conducted market research
analyses that suggest sales of $500m three years’ post-launch, rising to $584m by
year five and $661m by year ten. "
In the above research from Trinity the first hurdle which is the EU regulatory pathway has been crosssed.
The numbers are absolutely huge when you look at a 20% royalty rate on those annual sales projections.
It points to multiples of the current share price.
Futura has done what is required by the regulators.
Hence it is now in the process of receiving the CE mark for the EU and has confirmed final study details with the FDA.
The regulators decide what goes on the market,not you.
Contrary to the previous poster.I see great hope.
Commercialisation update
"In conjunction with the regulatory processes, Futura has been working with retained specialised corporate advisers on active commercial discussions with potential licensing and marketing partners.
Following the Company's recent announcement of a Joint Collaboration agreement for the China and the South East Asia region, partnering discussions for other countries continue in line with the agreed process being managed by Futura's corporate advisers. The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000."
I am happy to let the Bod get on with running the business.
This is what David Ralph said in full
"The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
KY jelly does not approach the efficacy of anything
You are fabricating truths again
All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile. MED3000 will be of high interest to the Medical Community for those patients who are seeking a very rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.
Dr Yacov Reisman
Consultant Urologist and Past President of the European Society of Sexual Medicine
That is pretty clear cut
What is quite clear is liambooth/lbo is not a urologist specialising in ED.
He is simply trying to spread doubt as was the case with Jonnybig and the butler on advfn,who by the way have mysteriously vanished.
A new incarnation turned up/
Those that are a singing praises about how Med3000 will likely be a first line treatment method for millions of sufferers.
Furthermore a glance at the market potential shows that this has "blockbuster" potential.even more so because it will go straight to OTC.
The previous broker forecasts split the sales into prescription only first,followed a few years later by OTC.
So from a commercial perspective Med3000 can cover the entire marketplace straight off the bat.
Angry and bitter doesn't translate into knowledge.
I would also draw your attention to how the Chinese investment partners who have commited up to £6 million see the product.
Yang Liu, Chairperson and Chief Investment Officer of Atlantis commented: "Through Riverwood we are delighted to provide financial support to the regional healthcare industry in Greater China and South East Asia to drive successful development and optimal commercialisation of medical therapies in the region. We are proud to be in the vanguard of collaborative efforts to bring important and innovative new disease therapies to market in Asia in a way that that maximises and eases access for patients in such a large region where we anticipate strong demand."
Alick Dong, Managing Director of Co-High commented: "We are pleased to initiate this joint collaboration with Futura and bring their clinically validated technology to China and Southeast Asia. We feel that MED3000 could significantly benefit individuals suffering from ED in these regions, generating significant value for Futura and Co-High in the process. We look forward to collaborating with Futura while bringing MED3000's immense potential to fruition"
If they get anywhere near £300 million annual sales they will be raking in £60 million a year in royalties.
On those numbers that assumes the men only buy twice a year.So in reality the numbers could end up exponentially higher.
Each of his posts becoming that of someone in despair.
He is so angry one has to laugh.
That brings in another £500,000 as equity on top of the £1,500,000 the Chinese have already invested.
That fills the coffer to the tune of another £500,000 on top of the £1.5 million the Chinese have already invested.
Looking good Houston
Something is definitely brewing as the company told us as much...
Commercialisation update
In conjunction with the regulatory processes, Futura has been working with retained specialised corporate advisers on active commercial discussions with potential licensing and marketing partners.
Following the Company's recent announcement of a Joint Collaboration agreement for the China and the South East Asia region, partnering discussions for other countries continue in line with the agreed process being managed by Futura's corporate advisers. The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000
You are back again comparing apples to oranges.
The first glaring differences is Med3000 is projected to have ten times the sales.
That is why the co put all it's energy into bringing Med3000 to market
Not often you can buy into a co that's market cap could end up the annual royalty rates.
Now heres the thing.The reason I say those numbers are uber conservative is that would mean those men only bought the products twice a year.
If you change it to twice a month(still very low) you get to annual sales of over £3 billion and well,20% of that is game changing stuff.
You don't see potential like that come around more than once or twice in a lifetime.
I note this from Liberum and think the number are actually very conservative
"Peak sales of £300m for MED3000: We believe that MED3000 is a
differentiated product that should be used as a first line therapy for newly
diagnosed ED patients. This gives it an addressable population of up to
400 million men in the US and EU5. With an experienced, well-funded and
incentivised partner, we think MED3000 can garner a c.20% market share
at a modest price premium to generic PDE-5s. Based on these
assumptions we believe MED3000 could realise peak sales of £300m per
annum."
Has anyone worked out what a 20% royalty on annual sales of £300 million is?
I Guess Liam changed his name from Odyseus in shame.He told everyone it was going down and the rest is history.
Judging by the increasing desperation of his posts I think this heralds a sharply higher share price after this recent healthy consolidation.
Th other point to remember that its been over 20 years since the launch of Viagra and despite hundreds of millions of dollars going into research,nobody has come up with anything better.
Futura have managed to create a product that beats the pants off it in terms of speed of onset ,has no side effects,can be used by the 20% of men that can't take Viagra.Plus it can be used by those already on Viagra to boost the effects.
Sorry for the double post